NICE recommend Eisai’s lenvatinib for treatment of advanced renal cell carcinoma

Eisai announced that NICE has given a positive recommendation for the use of lenvatinib in combination with everolimus to treat adults with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. The company also provides lenvatinib

Continue Reading

Eisai Joins Up With Valeant To Promote Halaven

After failing to gain approval from UK cost watchdog, NICE, for the use of Halaven in treating breast cancer, Eisai has linked up with Valeant Pharmaceuticals International, to promote the drug in Central and Eastern Europe. Halaven received European Commission approval in March 2011. Valeant’s PharmaSwiss division will distribute Halaven (eribulin) in Bulgaria, Romania, Latvia,

Continue Reading